Shares of OptiNose Inc (NASDAQ:OPTN) have been assigned an average broker rating score of 1.33 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and two have issued a strong buy rating on the company.
Brokers have set a twelve-month consensus target price of $29.67 for the company, according to Zacks. Zacks has also given OptiNose an industry rank of 103 out of 265 based on the ratings given to related companies.
OPTN has been the topic of several analyst reports. BMO Capital Markets initiated coverage on OptiNose in a report on Tuesday, November 7th. They set an “outperform” rating and a $29.00 price target on the stock. Jefferies Group assumed coverage on shares of OptiNose in a report on Tuesday, November 7th. They issued a “buy” rating and a $27.00 price objective on the stock. Piper Jaffray Companies assumed coverage on OptiNose in a research report on Tuesday, November 7th. They issued an “overweight” rating and a $27.00 target price for the company. Finally, Royal Bank Of Canada assumed coverage on OptiNose in a research report on Tuesday, November 7th. They set an “outperform” rating and a $33.00 price objective for the company.
OptiNose (NASDAQ:OPTN) opened at $18.98 on Tuesday. OptiNose has a fifty-two week low of $15.01 and a fifty-two week high of $21.46.
TRADEMARK VIOLATION NOTICE: “OptiNose Inc (OPTN) Given Consensus Recommendation of “Strong Buy” by Brokerages” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/05/optinose-inc-optn-given-consensus-recommendation-of-strong-buy-by-brokerages.html.
OptiNose Company Profile
OptiNose, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of products for patients treated by ear, nose and throat, or ENT, and allergy specialists. The Company’s products candidates include XHANCE (Nasal Polyps), XHANCE (Chornic Sinusitis) OPN-300, OPN-021, and other.
Get a free copy of the Zacks research report on OptiNose (OPTN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose Inc and related companies with MarketBeat.com's FREE daily email newsletter.